染色质环境中的 DNA 错配修复：机制与治疗潜力。
DNA mismatch repair in the chromatin context: Mechanisms and therapeutic potential.
机构信息
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, 75390, USA.
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, 75390, USA.
出版信息
DNA Repair (Amst). 2020 Sep;93:102918. doi: 10.1016/j.dnarep.2020.102918.
Abstract
DNA mismatch repair (MMR) maintains genomic stability primarily by correcting replication errors. Defects in MMR lead to cancers and cause resistance to many chemotherapeutic drugs. Emerging evidence reveals that MMR is coupled with replication and precisely regulated in the context of chromatin; strikingly, tumors defective in MMR are highly responsive to immune checkpoint blockade therapy. As a tribute to Dr. Samuel Wilson for his many scientific contributions to the field of DNA repair and his leadership as Editor-in-Chief of the journal DNA Repair, we summarize recent developments in research on MMR at the chromatin level, its implications for tumorigenesis, and its therapeutic potential.
摘要
DNA 错配修复 (MMR) 主要通过纠正复制错误来维持基因组稳定性。MMR 的缺陷会导致癌症，并导致许多化疗药物产生耐药性。新出现的证据表明，MMR 与复制相关联，并在染色质的背景下得到精确调控；引人注目的是，MMR 缺陷的肿瘤对免疫检查点阻断治疗高度敏感。为了向 Dr. Samuel Wilson 对 DNA 修复领域的众多科学贡献以及作为该杂志 DNA 修复主编的领导表示敬意，我们总结了染色质水平上 MMR 研究的最新进展、其对肿瘤发生的影响及其治疗潜力。
相似文献
1
DNA mismatch repair in the chromatin context: Mechanisms and therapeutic potential.染色质环境中的 DNA 错配修复：机制与治疗潜力。
DNA Repair (Amst). 2020 Sep;93:102918. doi: 10.1016/j.dnarep.2020.102918.
2
DNA mismatch repair-dependent DNA damage responses and cancer.DNA 错配修复依赖性 DNA 损伤反应与癌症。
DNA Repair (Amst). 2020 Sep;93:102923. doi: 10.1016/j.dnarep.2020.102923.
3
The mismatch repair-dependent DNA damage response: Mechanisms and implications.错配修复依赖性 DNA 损伤反应：机制与意义。
DNA Repair (Amst). 2019 Jun;78:60-69. doi: 10.1016/j.dnarep.2019.03.009. Epub 2019 Apr 1.
4
New insights and challenges in mismatch repair: getting over the chromatin hurdle.错配修复中的新见解与挑战：跨越染色质障碍
DNA Repair (Amst). 2014 Jul;19:48-54. doi: 10.1016/j.dnarep.2014.03.027. Epub 2014 Apr 24.
5
Chromatin remodeling and mismatch repair: Access and excision.染色质重塑和错配修复：进入和切除。
DNA Repair (Amst). 2020 Jan;85:102733. doi: 10.1016/j.dnarep.2019.102733. Epub 2019 Oct 17.
6
DNA mismatch repair in the context of chromatin.染色质背景下的DNA错配修复
Cell Biosci. 2020 Feb 3;10:10. doi: 10.1186/s13578-020-0379-7. eCollection 2020.
7
Exploiting DNA mismatch repair deficiency as a therapeutic strategy.利用DNA错配修复缺陷作为一种治疗策略。
Exp Cell Res. 2014 Nov 15;329(1):110-5. doi: 10.1016/j.yexcr.2014.07.004. Epub 2014 Jul 11.
8
Mismatch repair defects in human carcinogenesis.人类致癌过程中的错配修复缺陷
Hum Mol Genet. 1996;5 Spec No:1489-94. doi: 10.1093/hmg/5.supplement_1.1489.
9
Approaches to diagnose DNA mismatch repair gene defects in cancer.癌症中DNA错配修复基因缺陷的诊断方法。
DNA Repair (Amst). 2016 Feb;38:147-154. doi: 10.1016/j.dnarep.2015.11.022. Epub 2015 Dec 8.
10
Targeting Mismatch Repair defects: A novel strategy for personalized cancer treatment.靶向错配修复缺陷：个性化癌症治疗的新策略。
DNA Repair (Amst). 2016 Feb;38:135-139. doi: 10.1016/j.dnarep.2015.11.026. Epub 2015 Dec 2.
引用本文的文献
1
Pre-Treatment Peripheral Blood Parameters as Prognostic Biomarkers in Cancer Patients Receiving Immune Checkpoint Inhibitors.接受免疫检查点抑制剂治疗的癌症患者治疗前外周血参数作为预后生物标志物
Int J Hematol Oncol Stem Cell Res. 2025 Jan 1;19(1):7-16. doi: 10.18502/ijhoscr.v19i1.17819.
2
RNA/DNA Binding Protein TDP43 Regulates DNA Mismatch Repair Genes with Implications for Genome Stability.RNA/DNA结合蛋白TDP43调控DNA错配修复基因，对基因组稳定性有影响。
bioRxiv. 2024 Nov 8:2024.05.16.594552. doi: 10.1101/2024.05.16.594552.
3
MutS functions as a clamp loader by positioning MutL on the DNA during mismatch repair.MutS 在错配修复过程中通过将 MutL 定位在 DNA 上来充当夹子加载器。
Nat Commun. 2022 Oct 3;13(1):5808. doi: 10.1038/s41467-022-33479-3.
4
Mutperiod: Analysis of periodic mutation rates in nucleosomes.Mutperiod：核小体中周期性突变率的分析
Comput Struct Biotechnol J. 2021 Jul 26;19:4177-4183. doi: 10.1016/j.csbj.2021.07.025. eCollection 2021.
5
DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy.DNA 损伤修复：靶向癌症治疗的历史观点、机制途径和临床转化。
Signal Transduct Target Ther. 2021 Jul 9;6(1):254. doi: 10.1038/s41392-021-00648-7.
本文引用的文献
1
DNA mismatch repair in the context of chromatin.染色质背景下的DNA错配修复
Cell Biosci. 2020 Feb 3;10:10. doi: 10.1186/s13578-020-0379-7. eCollection 2020.
2
SMARCAD1-mediated recruitment of the DNA mismatch repair protein MutLα to MutSα on damaged chromatin induces apoptosis in human cells.SMARCAD1 介导的 DNA 错配修复蛋白 MutLα 募集到受损染色质上的 MutSα 诱导人细胞凋亡。
J Biol Chem. 2020 Jan 24;295(4):1056-1065. doi: 10.1074/jbc.RA119.008854. Epub 2019 Dec 16.
3
Understanding histone H3 lysine 36 methylation and its deregulation in disease.理解组蛋白 H3 赖氨酸 36 位甲基化及其在疾病中的失调。
Cell Mol Life Sci. 2019 Aug;76(15):2899-2916. doi: 10.1007/s00018-019-03144-y. Epub 2019 May 30.
4
Cancer-driving H3G34V/R/D mutations block H3K36 methylation and H3K36me3-MutSα interaction.致癌的 H3G34V/R/D 突变阻断 H3K36 甲基化和 H3K36me3-MutSα 相互作用。
Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):9598-9603. doi: 10.1073/pnas.1806355115. Epub 2018 Sep 4.
5
Nucleosomes around a mismatched base pair are excluded via an Msh2-dependent reaction with the aid of SNF2 family ATPase Smarcad1.错配碱基对周围的核小体通过 Msh2 依赖性反应排除，该反应借助于 SNF2 家族 ATP 酶 Smarcad1。
Genes Dev. 2018 Jun 1;32(11-12):806-821. doi: 10.1101/gad.310995.117. Epub 2018 Jun 13.
6
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.ARID1A 缺失可促进突变并增强免疫检查点阻断引发的抗肿瘤治疗性免疫。
Nat Med. 2018 May;24(5):556-562. doi: 10.1038/s41591-018-0012-z. Epub 2018 May 7.
7
H3K36me3-mediated mismatch repair preferentially protects actively transcribed genes from mutation.H3K36me3 介导的错配修复优先保护活跃转录的基因免受突变。
J Biol Chem. 2018 May 18;293(20):7811-7823. doi: 10.1074/jbc.RA118.002839. Epub 2018 Apr 2.
8
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.错配修复缺陷可预测实体瘤对程序性死亡受体1（PD-1）阻断疗法的反应。
Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.
9
Molecular basis for oncohistone H3 recognition by SETD2 methyltransferase.SETD2甲基转移酶识别致癌组蛋白H3的分子基础。
Genes Dev. 2016 Jul 15;30(14):1611-6. doi: 10.1101/gad.284323.116.
10
The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas.组蛋白H3.3K36M突变可重编程软骨母细胞瘤的表观基因组。
Science. 2016 Jun 10;352(6291):1344-8. doi: 10.1126/science.aae0065. Epub 2016 May 26.
Zotero 插件